.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Queensland Health
Johnson and Johnson
Teva
Cantor Fitzgerald
Julphar
US Department of Justice
Harvard Business School
Chinese Patent Office
Federal Trade Commission

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 078964

« Back to Dashboard
NDA 078964 describes RABEPRAZOLE SODIUM, which is a drug marketed by Teva Pharms Usa, Dr Reddys Labs Ltd, Breckenridge Pharm, Aurobindo Pharma Ltd, Lupin Ltd, Torrent Pharms Ltd, Kremers Urban Pharms, Amneal Pharms, and Mylan Pharms Inc, and is included in nine NDAs. It is available from eighteen suppliers. Additional details are available on the RABEPRAZOLE SODIUM profile page.

The generic ingredient in RABEPRAZOLE SODIUM is rabeprazole sodium. There are twenty-nine drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

Summary for 078964

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 078964

Mechanism of ActionProton Pump Inhibitors

Medical Subject Heading (MeSH) Categories for 078964

Suppliers and Packaging for NDA: 078964

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RABEPRAZOLE SODIUM
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL 078964 ANDA Proficient Rx LP 63187-788 63187-788-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (63187-788-30)
RABEPRAZOLE SODIUM
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL 078964 ANDA Proficient Rx LP 63187-788 63187-788-60 60 TABLET, DELAYED RELEASE in 1 BOTTLE (63187-788-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength20MG
Approval Date:Nov 8, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cantor Fitzgerald
Accenture
Teva
Citi
Merck
Baxter
Cipla
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot